C5938
Complement factor I from human plasma
>90% (SDS-PAGE)
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
CAS Number:
MDL number:
UNSPSC Code:
12352204
NACRES:
NA.54
Recommended Products
Application
Complement factor I from human plasma has been used in a case study of glucose-starved Staphylococcus aureus. Complement factor I from human plasma has also been used to study the human complement cascade of proteolysis as a target of laser irradiation.
Biochem/physiol Actions
Protease which cleaves and inactivates C3b and C4b
Physical form
Supplied as a 1mg/ml solution in PBS, pH 7.2
Other Notes
View more information on the complement pathway at www.sigma-aldrich.com/enzymeexplorer
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Storage Class Code
10 - Combustible liquids
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
The study of the human complement cascade of proteolysis as a target of laser irradiation
Galebskaia, L., et al.
Biomeditsinskaia Khimiia, 55, 68-72 (2012)
Sara C Nilsson et al.
Molecular immunology, 48(14), 1611-1620 (2011-05-03)
Factor I (FI) is a crucial inhibitor controlling all complement pathways due to its ability to degrade activated complement proteins C3b and C4b in the presence of cofactors such as factor H, C4b-binding protein, complement receptor 1 or CD46. Complete
Andrew S Bomback et al.
Clinical journal of the American Society of Nephrology : CJASN, 7(5), 748-756 (2012-03-10)
The principle defect in dense deposit disease and C3 glomerulonephritis is hyperactivity of the alternative complement pathway. Eculizumab, a monoclonal antibody that binds to C5 to prevent formation of the membrane attack complex, may prove beneficial. In this open-label, proof
Maren Sullivan et al.
Annals of human genetics, 75(6), 639-647 (2011-09-13)
Hereditary atypical hemolytic uremic syndrome (aHUS), a dramatic disease frequently leading to dialysis, is associated with germline mutations of the CFH, CD46, or CFI genes. After identification of the mutation in an affected aHUS patient, single-site gene testing of relatives
G S Reusz et al.
Transplantation proceedings, 43(4), 1247-1249 (2011-05-31)
Hemolytic uremic syndrome (HUS) is a rare disease with various etiologies, making the identification of the specific forms and appropriate treatment difficult. Therefore, clinical and laboratory data from these patients need to be analyzed in national and international registries. Herein
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service